• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LILRB1-HLA-G 轴定义了一个检查点,驱动结核分枝杆菌自然杀伤细胞衰竭。

LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis.

机构信息

CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.

Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.

出版信息

EMBO Mol Med. 2024 Aug;16(8):1755-1790. doi: 10.1038/s44321-024-00106-1. Epub 2024 Jul 19.

DOI:10.1038/s44321-024-00106-1
PMID:39030302
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11319715/
Abstract

Chronic infections, including Mycobacterium tuberculosis (Mtb)-caused tuberculosis (TB), can induce host immune exhaustion. However, the key checkpoint molecules involved in this process and the underlying regulatory mechanisms remain largely undefined, which impede the application of checkpoint-based immunotherapy in infectious diseases. Here, through adopting time-of-flight mass cytometry and transcriptional profiling to systematically analyze natural killer (NK) cell surface receptors, we identify leukocyte immunoglobulin like receptor B1 (LILRB1) as a critical checkpoint receptor that defines a TB-associated cell subset (LILRB1 NK cells) and drives NK cell exhaustion in TB. Mechanistically, Mtb-infected macrophages display high expression of human leukocyte antigen-G (HLA-G), which upregulates and activates LILRB1 on NK cells to impair their functions by inhibiting mitogen-activated protein kinase (MAPK) signaling via tyrosine phosphatases SHP1/2. Furthermore, LILRB1 blockade restores NK cell-dependent anti-Mtb immunity in immuno-humanized mice. Thus, LILRB1-HLA-G axis constitutes a NK cell immune checkpoint in TB and serves as a promising immunotherapy target.

摘要

慢性感染,包括由结核分枝杆菌(Mtb)引起的结核病(TB),可诱导宿主免疫衰竭。然而,这一过程中涉及的关键检查点分子和潜在的调节机制在很大程度上仍未得到明确,这阻碍了基于检查点的免疫疗法在传染病中的应用。在这里,我们通过采用飞行时间质谱流式细胞术和转录谱分析系统地分析自然杀伤(NK)细胞表面受体,鉴定出白细胞免疫球蛋白样受体 B1(LILRB1)作为一个关键的检查点受体,它定义了一个与 TB 相关的细胞亚群(LILRB1 NK 细胞),并在 TB 中驱动 NK 细胞衰竭。从机制上讲,感染了 Mtb 的巨噬细胞显示出高水平的人白细胞抗原-G(HLA-G),其上调并激活 NK 细胞上的 LILRB1,通过酪氨酸磷酸酶 SHP1/2 抑制丝裂原活化蛋白激酶(MAPK)信号传导,从而损害其功能。此外,LILRB1 阻断恢复了免疫人源化小鼠中 NK 细胞依赖的抗 Mtb 免疫。因此,LILRB1-HLA-G 轴构成了 TB 中的 NK 细胞免疫检查点,并可作为有前途的免疫治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/b1c2c8e8fbd2/44321_2024_106_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/6a1662689f36/44321_2024_106_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/921a295834f8/44321_2024_106_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/afd7f5c5515d/44321_2024_106_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/9f8950813b0a/44321_2024_106_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/14bc576b7a41/44321_2024_106_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/aea077bfe75e/44321_2024_106_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/0e04ca3aa10a/44321_2024_106_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/89c5e7d21837/44321_2024_106_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/5473ad71e023/44321_2024_106_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/1afe8255b240/44321_2024_106_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/c6134e0c0dce/44321_2024_106_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/fb54423a5001/44321_2024_106_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/b1c2c8e8fbd2/44321_2024_106_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/6a1662689f36/44321_2024_106_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/921a295834f8/44321_2024_106_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/afd7f5c5515d/44321_2024_106_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/9f8950813b0a/44321_2024_106_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/14bc576b7a41/44321_2024_106_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/aea077bfe75e/44321_2024_106_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/0e04ca3aa10a/44321_2024_106_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/89c5e7d21837/44321_2024_106_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/5473ad71e023/44321_2024_106_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/1afe8255b240/44321_2024_106_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/c6134e0c0dce/44321_2024_106_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/fb54423a5001/44321_2024_106_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ec5/11319715/b1c2c8e8fbd2/44321_2024_106_Fig13_ESM.jpg

相似文献

1
LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis.LILRB1-HLA-G 轴定义了一个检查点,驱动结核分枝杆菌自然杀伤细胞衰竭。
EMBO Mol Med. 2024 Aug;16(8):1755-1790. doi: 10.1038/s44321-024-00106-1. Epub 2024 Jul 19.
2
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.靶向 LILRB1 在癌症固有和适应性免疫检查点治疗中的研究进展。
Front Immunol. 2023 Sep 13;14:1240275. doi: 10.3389/fimmu.2023.1240275. eCollection 2023.
3
Human Leukocyte Antigen-G Inhibits the Anti-Tumor Effect of Natural Killer Cells via Immunoglobulin-Like Transcript 2 in Gastric Cancer.人类白细胞抗原-G通过免疫球蛋白样转录物2抑制胃癌中自然杀伤细胞的抗肿瘤作用。
Cell Physiol Biochem. 2017;44(5):1828-1841. doi: 10.1159/000485819. Epub 2017 Dec 7.
4
Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells.拮抗型抗 LILRB1 单克隆抗体调节自然杀伤细胞的抗肿瘤功能。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2019-000515.
5
Effect of cytomegalovirus infection and leukocyte immunoglobulin like receptor B1 polymorphisms on receptor expression in peripheral blood mononuclear cells.巨细胞病毒感染和白细胞免疫球蛋白样受体B1基因多态性对人外周血单个核细胞中该受体表达的影响
Microbiol Immunol. 2018 Dec;62(12):755-762. doi: 10.1111/1348-0421.12661.
6
Inhibiting HLA-G restores IFN-γ and TNF-α producing T cell in pleural Tuberculosis.抑制HLA-G可恢复胸膜结核中产生IFN-γ和TNF-α的T细胞。
Tuberculosis (Edinb). 2018 Mar;109:69-79. doi: 10.1016/j.tube.2018.01.008. Epub 2018 Feb 6.
7
LILRB1 polymorphisms influence posttransplant HCMV susceptibility and ligand interactions.LILRB1 多态性影响移植后 HCMV 的易感性和配体相互作用。
J Clin Invest. 2018 Apr 2;128(4):1523-1537. doi: 10.1172/JCI96174. Epub 2018 Mar 12.
8
Soluble human leukocyte antigen-g5 activates extracellular signal-regulated protein kinase signaling and stimulates trophoblast invasion.可溶性人白细胞抗原-G5 激活细胞外信号调节蛋白激酶信号通路并刺激滋养层细胞侵袭。
PLoS One. 2013 Oct 1;8(10):e76023. doi: 10.1371/journal.pone.0076023. eCollection 2013.
9
LILRB1 polymorphism and surface phenotypes of natural killer cells.LILRB1 多态性与自然杀伤细胞的表面表型。
Hum Immunol. 2010 Oct;71(10):942-9. doi: 10.1016/j.humimm.2010.06.015. Epub 2010 Jun 30.
10
Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex.四Ig样结构域LILRB2、四结构域LILRB1与HLA-G1复合物的结构。
Cell Mol Immunol. 2020 Sep;17(9):966-975. doi: 10.1038/s41423-019-0258-5. Epub 2019 Jul 4.

引用本文的文献

1
Inhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications.人类疾病中的抑制性白细胞免疫球蛋白样受体B亚家族(LILRBs):结构、作用、机制及临床应用
Theranostics. 2025 Jul 25;15(16):8222-8258. doi: 10.7150/thno.116951. eCollection 2025.
2
Immune dysregulation in endometrial tuberculosis: elevated HLA-G and IL-1Ra as key modulators.子宫内膜结核中的免疫失调:HLA-G和IL-1Ra升高作为关键调节因子。
Front Cell Infect Microbiol. 2025 May 1;15:1548238. doi: 10.3389/fcimb.2025.1548238. eCollection 2025.
3
NCAM1-SHIP2 axis upon recognizing microbes inhibits the expressions of inflammatory factors through P38-H3K4me and P38-NF-κB pathways in oyster.

本文引用的文献

1
TRIM27 elicits protective immunity against tuberculosis by activating TFEB-mediated autophagy flux.TRIM27 通过激活 TFEB 介导的自噬通量来引发针对结核病的保护性免疫。
Autophagy. 2024 Jul;20(7):1483-1504. doi: 10.1080/15548627.2024.2321831. Epub 2024 Mar 4.
2
Immune cell interactions in tuberculosis.结核分枝杆菌感染中的免疫细胞相互作用。
Cell. 2022 Dec 8;185(25):4682-4702. doi: 10.1016/j.cell.2022.10.025.
3
A bacterial phospholipid phosphatase inhibits host pyroptosis by hijacking ubiquitin.一种细菌磷脂酶通过劫持泛素抑制宿主细胞焦亡。
NCAM1-SHIP2轴在识别微生物后,通过P38-H3K4me和P38-NF-κB途径抑制牡蛎中炎症因子的表达。
Cell Commun Signal. 2025 Feb 20;23(1):102. doi: 10.1186/s12964-025-02087-1.
Science. 2022 Oct 14;378(6616):eabq0132. doi: 10.1126/science.abq0132.
4
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.BND-22,一种首创的人源化 ILT2 阻断抗体,可促进抗肿瘤免疫和肿瘤消退。
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-004859.
5
Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control.多模态分析恒河猴肺部肉芽肿揭示了结核分枝杆菌控制的细胞相关性。
Immunity. 2022 May 10;55(5):827-846.e10. doi: 10.1016/j.immuni.2022.04.004. Epub 2022 Apr 27.
6
The immunoregulatory landscape of human tuberculosis granulomas.人类结核肉芽肿的免疫调节景观。
Nat Immunol. 2022 Feb;23(2):318-329. doi: 10.1038/s41590-021-01121-x. Epub 2022 Jan 20.
7
Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.HLA-G 与 NK 细胞受体 KIR2DL4 的相互作用调控 HER2 阳性乳腺癌对曲妥珠单抗的耐药性。
Signal Transduct Target Ther. 2021 Jun 23;6(1):236. doi: 10.1038/s41392-021-00629-w.
8
Human NK cells, their receptors and function.人自然杀伤细胞、其受体和功能。
Eur J Immunol. 2021 Jul;51(7):1566-1579. doi: 10.1002/eji.202049028. Epub 2021 May 10.
9
Beyond immune checkpoint blockade: emerging immunological strategies.超越免疫检查点阻断:新兴的免疫学策略。
Nat Rev Drug Discov. 2021 Dec;20(12):899-919. doi: 10.1038/s41573-021-00155-y. Epub 2021 Mar 8.
10
PD-1 blockade exacerbates infection in rhesus macaques.PD-1 阻断加剧恒河猴感染。
Sci Immunol. 2021 Jan 15;6(55). doi: 10.1126/sciimmunol.abf3861.